| Title |
Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype
|
|---|---|
| Published in |
Medical Oncology, March 2015
|
| DOI | 10.1007/s12032-015-0589-8 |
| Pubmed ID | |
| Authors |
Jiujie Cui, Ming Quan, Weihua Jiang, Hai Hu, Feng Jiao, Ning Li, Ziliang Jin, Lei Wang, Yu Wang, Liwei Wang |
| Abstract |
Lactate dehydrogenase B (LDHB) is widely expressed in adult somatic tissue and is one of the two subunits of lactate dehydrogenase, which is the key glycolytic enzyme and catalyzes the interconversion of pyruvate and lactate. However, the roles of LDHB in glycolysis and tumor progression were obscure in different types of cancer. Here, we determined the roles of LDHB in pancreatic cancer development and progression. We found suppressed expression of LDHB in pancreatic cancer which was due to promoter hypermethylation and deceased expression of LDHB led to glycolytic transition. Functional analysis revealed that suppressed expression of LDHB promoted pancreatic cancer cells proliferation, invasion, and migration in hypoxia. Thus, LDHB might function as a suppressor of glycolysis and suppressed pancreatic cancer progression. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 25 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 28% |
| Student > Bachelor | 7 | 28% |
| Student > Doctoral Student | 2 | 8% |
| Researcher | 2 | 8% |
| Student > Master | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 5 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 8 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 16% |
| Medicine and Dentistry | 4 | 16% |
| Agricultural and Biological Sciences | 2 | 8% |
| Immunology and Microbiology | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 5 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2015.
All research outputs
#17,751,741
of 22,796,179 outputs
Outputs from Medical Oncology
#730
of 1,291 outputs
Outputs of similar age
#180,125
of 263,459 outputs
Outputs of similar age from Medical Oncology
#12
of 43 outputs
Altmetric has tracked 22,796,179 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,291 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,459 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.